From 84206b838dd9e067d1b829364238c8ae0d9c933f Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Sun, 3 May 2026 04:34:04 +0000 Subject: [PATCH] vida: extract claims from 2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure - Source: inbox/queue/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure.md - Domain: health - Claims: 0, Entities: 1 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...-through-mesolimbic-dopamine-modulation.md | 7 +++ entities/health/evoke-evoke-plus-trials.md | 50 +++++++++++++++++++ ...s-semaglutide-alzheimers-phase3-failure.md | 5 +- 3 files changed, 61 insertions(+), 1 deletion(-) create mode 100644 entities/health/evoke-evoke-plus-trials.md rename inbox/{queue => archive/health}/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure.md (98%) diff --git a/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md b/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md index e5d2413f2..c5838cf0d 100644 --- a/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md +++ b/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md @@ -74,3 +74,10 @@ First RCT evidence: 26-week trial of 108 AUD+obesity patients showed semaglutide **Source:** Clinical Trial Vanguard 2026-04-01 Concurrent psychotropic medication use (antidepressants, benzodiazepines) shows OR 4.07-4.45 for suicidality in GLP-1 users, suggesting the dopaminergic mechanism may interact adversely with psychiatric medications rather than uniformly benefiting substance use disorder patients. The protective AUD signal may be specific to metabolic disease + AUD comorbidity rather than primary psychiatric AUD. + + +## Extending Evidence + +**Source:** The Lancet 2026, EVOKE/EVOKE+ Phase 3 failure + +EVOKE/EVOKE+ Alzheimer's failure provides critical boundary evidence for GLP-1 CNS mechanism specificity. Semaglutide succeeds in addiction (VTA dopamine reward circuits) but fails in neurodegeneration (amyloid/tau pathways), demonstrating that GLP-1 receptor activation produces pathway-specific effects rather than broad neuroprotection. This supports the mesolimbic dopamine mechanism for addiction while ruling out generalized CNS benefit claims. diff --git a/entities/health/evoke-evoke-plus-trials.md b/entities/health/evoke-evoke-plus-trials.md new file mode 100644 index 000000000..a6ae82ba6 --- /dev/null +++ b/entities/health/evoke-evoke-plus-trials.md @@ -0,0 +1,50 @@ +# EVOKE/EVOKE+ Trials + +**Type:** Phase 3 clinical trials +**Sponsor:** Novo Nordisk +**Intervention:** Oral semaglutide 14mg (flexible dose) +**Indication:** Early-stage symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia with confirmed amyloid positivity) +**Status:** Failed (2026) + +## Trial Design + +- **Design:** Two parallel Phase 3, double-blind, placebo-controlled trials +- **Population:** n=3,808 total, ages 55-85 +- **Duration:** 104 weeks primary endpoint, 156 weeks extended follow-up +- **Primary endpoints:** Cognitive and global decline measures + +## Results + +**Primary endpoints:** Not met in either trial. Semaglutide did not demonstrate superiority to placebo in slowing cognitive or global decline. + +**Secondary endpoints:** +- No delay in time to progression to dementia (MCI subgroup, pooled analysis) +- **Biomarker findings:** Up to 10% reduction in CSF core AD biomarkers (amyloid, tau) +- Significant reductions in CSF neuroinflammation markers +- **Critical gap:** Biomarker improvements did not translate to clinical benefit + +## Scientific Interpretation + +The biomarker-clinical benefit dissociation suggests three possible explanations: +1. Dose insufficient to produce clinical effect despite biomarker change +2. Treatment window too late (early symptomatic disease already past intervention point) +3. Neuroinflammation/AD pathobiology not rate-limiting in this population + +## Implications + +**For GLP-1 CNS expansion:** Establishes mechanism specificity boundary. Semaglutide shows efficacy in addiction (VTA dopamine pathways) but not neurodegeneration (amyloid/tau pathways), indicating GLP-1 CNS effects are pathway-specific rather than universally neuroprotective. + +**For Alzheimer's drug development:** Adds to evidence that biomarker improvement (even in core AD pathology markers) does not guarantee clinical benefit, raising questions about surrogate endpoint validity. + +**For prevention vs. treatment:** May indicate GLP-1 has preventive rather than therapeutic value in neurodegeneration, requiring different trial design in at-risk populations. + +## Timeline + +- **2026-04-15** — Results published in The Lancet +- **2026-04** — Novo Nordisk announces discontinuation of 1-year extension periods for both trials + +## Sources + +- The Lancet (2026): "Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials" +- Alzheimer's Drug Discovery Foundation analysis +- NeurologyLive coverage \ No newline at end of file diff --git a/inbox/queue/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure.md b/inbox/archive/health/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure.md similarity index 98% rename from inbox/queue/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure.md rename to inbox/archive/health/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure.md index abd6f7ced..b649c272b 100644 --- a/inbox/queue/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure.md +++ b/inbox/archive/health/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure.md @@ -7,10 +7,13 @@ date: 2026-04-15 domain: health secondary_domains: [] format: research-article -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-05-03 priority: medium tags: [GLP-1, semaglutide, Alzheimers, neurodegeneration, Phase-3, clinical-failure, biomarker-gap, CNS] intake_tier: research-task +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content